Cargando…

The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes

BACKGROUND: A delay in reaching HbA1c targets in patients with newly-diagnosed type 2 diabetes (T2D) is associated with an increased long-term risk of developing cardiovascular diseases (CVD), a phenomenon referred to as legacy effect. Whether an early introduction of glucose-lowering drugs with pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ceriello, Antonio, Lucisano, Giuseppe, Prattichizzo, Francesco, La Grotta, Rosalba, Frigé, Chiara, De Cosmo, Salvatore, Di Bartolo, Paolo, Di Cianni, Graziano, Fioretto, Paola, Giorda, Carlo Bruno, Pontremoli, Roberto, Russo, Giuseppina, Viazzi, Francesca, Nicolucci, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398589/ https://www.ncbi.nlm.nih.gov/pubmed/37547276 http://dx.doi.org/10.1016/j.lanepe.2023.100666

Ejemplares similares

Erratum. Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. Diabetes Care 2019;42:514–519
por: Ceriello, Antonio, et al.
Publicado: (2020)

Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus
por: Viazzi, Francesca, et al.
Publicado: (2017)

Metabolic syndrome, serum uric acid and renal risk in patients with T2D
por: Viazzi, Francesca, et al.
Publicado: (2017)

HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target
por: Ceriello, Antonio, et al.
Publicado: (2022)

Diabetic kidney disease in the elderly: prevalence and clinical correlates
por: Russo, Giuseppina T., et al.
Publicado: (2018)

Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative
por: Lamacchia, Olga, et al.
Publicado: (2018)

Predictors of chronic kidney disease in type 2 diabetes: A longitudinal study from the AMD Annals initiative
por: De Cosmo, Salvatore, et al.
Publicado: (2016)

Publisher Correction: Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative
por: Piscitelli, Pamela, et al.
Publicado: (2018)

Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative
por: Piscitelli, Pamela, et al.
Publicado: (2017)

Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function
por: Gentile, Sandro, et al.
Publicado: (2017)

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes
por: Mirijello, Antonio, et al.
Publicado: (2018)

Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms
por: Sardu, Celestino, et al.
Publicado: (2022)

Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions
por: Gentile, Sandro, et al.
Publicado: (2018)

Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register
por: Ceriello, Antonio, et al.
Publicado: (2021)

Role of telemedicine during COVID-19 pandemic in type 2 diabetes outpatients: The AMD annals initiative
por: Russo, Giuseppina T., et al.
Publicado: (2022)

Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin
por: La Grotta, Rosalba, et al.
Publicado: (2022)

Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations
por: Leoncini, Giovanna, et al.
Publicado: (2020)

The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes
por: Forlani, Gabriele, et al.
Publicado: (2016)

SIRT3 mediates the effects of PCSK9 inhibitors on inflammation, autophagy, and oxidative stress in endothelial cells
por: D'Onofrio, Nunzia, et al.
Publicado: (2023)

SGLT2is and Renal Protection: From Biological Mechanisms to Real-World Clinical Benefits
por: Leoncini, Giovanna, et al.
Publicado: (2021)

Rapid-Acting Insulin Analogues Versus Regular Human Insulin: A Meta-Analysis of Effects on Glycemic Control in Patients with Diabetes
por: Nicolucci, Antonio, et al.
Publicado: (2019)

The “Metabolic Memory” Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications
por: Testa, Roberto, et al.
Publicado: (2017)

Pharmacological management of COVID-19 in type 2 diabetes
por: Ceriello, Antonio, et al.
Publicado: (2021)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

Postprandial Hyperglycemia and Cardiovascular Disease: Is the HEART2D study the answer?
por: Ceriello, Antonio
Publicado: (2009)

SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2023)

The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory
por: Pujadas, Gemma, et al.
Publicado: (2016)

Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes
por: Marfella, Raffaele, et al.
Publicado: (2022)

Factors Associated with Beta-Cell Dysfunction in Type 2 Diabetes: The BETADECLINE Study
por: Russo, Giuseppina T., et al.
Publicado: (2014)

Hyperglycemia and COVID-19: What was known and what is really new?
por: Ceriello, Antonio
Publicado: (2020)

Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus
por: Russo, Giuseppina, et al.
Publicado: (2015)

Variability of risk factors and diabetes complications
por: Ceriello, Antonio, et al.
Publicado: (2021)

Antihypertensive Treatment in Diabetic Kidney Disease: The Need for a Patient-Centered Approach
por: Bonino, Barbara, et al.
Publicado: (2019)

Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
por: Schnell, Oliver, et al.
Publicado: (2020)

Postprandial Hyperglycemia and Glycemic Variability: Should we care?
por: Standl, Eberhard, et al.
Publicado: (2011)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
por: Castaneda, Francisco, et al.
Publicado: (2007)

Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative
por: Manicardi, Valeria, et al.
Publicado: (2016)

Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory
por: Ceriello, Antonio
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k5qd2s73qgugeqc89dlk00u9ok